Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

If you have ever wondered whether Vertex Pharmaceuticals is a bargain right now, you are not alone. Let's break down whether the current price really stacks up to the company's fundamentals. Despite ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Abstract: Vertex-frequency analysis (VFA) is a useful technique in graph signal processing to extract the correspondence between frequencies and vertices. VFA can be calculated by the windowed graph ...

VERTEX SECURITIES LTD - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a bullish ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is expanding ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has approved ...